Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer.

Hironaga SatakeYoshinori KagawaEiji ShinozakiYoshinori TanizawaLong JinZhihong CaiAkitaka Makiyama

Published in: Advances in therapy (2022)

Real-world data revealed that all three antiangiogenic drugs were used as second-line therapy after first-line anti-EGFR antibodies and showed similar treatment durations.

Keyphrases

epidermal growth factor receptor
metastatic colorectal cancer
data analysis
tyrosine kinase
advanced non small cell lung cancer
small cell lung cancer
electronic health record
big data
replacement therapy
machine learning